Bone Biologics Corp (BBLG)
2025-06-30 | 2025-03-31 | 2024-09-30 | 2024-06-30 | |
|---|---|---|---|---|
| Revenues | - | - | - | - |
| Research and development | 191,608 | 423,576 | 429,747 | 350,442 |
| General and administrative | 556,467 | 614,910 | 521,274 | 459,223 |
| Total operating expenses | 748,075 | 1,038,486 | 951,021 | 809,665 |
| Loss from operations | -748,075 | -1,038,486 | -951,021 | -809,665 |
| Interest income | 6,654 | 20,039 | 19,993 | 15,147 |
| Change in fair value of warrant liability | -902 | -1,355 | 9,974 | -10,785 |
| Total other income | 7,556 | 21,394 | 10,019 | 25,932 |
| Net loss | -740,519 | -1,017,092 | -4,153,506 | -783,733 |
| Non cash deemed dividend | - | - | 3,212,504 | - |
| Net loss attributable to common stockholders | - | - | -4,153,506 | - |
| Loss per share - basic | -1.33 | -0.32 | -2.37 | 0.67 |
| Loss per share - diluted | -1.33 | -0.32 | -2.37 | 0.67 |
| Weighted average shares outstanding - basic | 557,787 | 3,183,191 | 1,753,409 | 1,168,423 |
| Weighted average shares outstanding - diluted | 557,787 | 3,183,191 | 1,753,409 | 1,168,423 |